The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
As of close of business last night, Candel Therapeutics Inc’s stock clocked out at $4.97, down -0.20% from its previous closing price of $4.98. In other words, the price has decreased by $-0.20 from its previous closing price. On the day, 0.94 million shares were traded. CADL stock price reached its highest trading level at $5.1888 during the session, while it also had its lowest trading level at $4.87.
Ratios:
To gain a deeper understanding of CADL’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.77 and its Current Ratio is at 2.77. In the meantime, Its Debt-to-Equity ratio is 0.20 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on February 20, 2025, initiated with a Buy rating and assigned the stock a target price of $25.
On February 19, 2025, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $20.
On February 07, 2025, BofA Securities started tracking the stock assigning a Buy rating and target price of $15.BofA Securities initiated its Buy rating on February 07, 2025, with a $15 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 18 ’25 when Nichols William Garrett sold 45,316 shares for $8.76 per share. The transaction valued at 396,995 led to the insider holds 52,493 shares of the business.
Barone Francesca sold 32,146 shares of CADL for $281,673 on Mar 18 ’25. The Chief Scientific Officer now owns 96,527 shares after completing the transaction at $8.76 per share. On Mar 18 ’25, another insider, Tak Paul Peter, who serves as the Chief Executive Officer of the company, sold 25,772 shares for $8.77 each. As a result, the insider received 226,023 and left with 226,140 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CADL now has a Market Capitalization of 236177376 and an Enterprise Value of 145577232.
Stock Price History:
The Beta on a monthly basis for CADL is -0.90, which has changed by -0.29503548 over the last 52 weeks, in comparison to a change of 0.097913146 over the same period for the S&P500. Over the past 52 weeks, CADL has reached a high of $14.60, while it has fallen to a 52-week low of $3.79. The 50-Day Moving Average of the stock is -30.64%, while the 200-Day Moving Average is calculated to be -24.51%.
Shares Statistics:
It appears that CADL traded 1.13M shares on average per day over the past three months and 951730 shares per day over the past ten days. A total of 46.93M shares are outstanding, with a floating share count of 34.58M. Insiders hold about 26.79% of the company’s shares, while institutions hold 33.86% stake in the company. Shares short for CADL as of 1744675200 were 5044330 with a Short Ratio of 4.47, compared to 1741910400 on 3451955. Therefore, it implies a Short% of Shares Outstanding of 5044330 and a Short% of Float of 13.55.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
As of right now, 1 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $-0.26, with high estimates of $-0.26 and low estimates of $-0.26.
Analysts are recommending an EPS of between $-0.92 and $-0.92 for the fiscal current year, implying an average EPS of $-0.92. EPS for the following year is $-0.95, with 1.0 analysts recommending between $-0.95 and $-0.95.
